Silicone Ahmed Glaucoma Valve With and Without Intravitreal Triamcinolone Acetonide for Neovascular Glaucoma: Randomized Clinical Trial

Detalhes bibliográficos
Autor(a) principal: Teixeira, Sergio Henrique [UNIFESP]
Data de Publicação: 2012
Outros Autores: Doi, Larissa Morimoto [UNIFESP], Silva, Andre Luiz de Freitas [UNIFESP], Silva, Karine Duarte [UNIFESP], Paes, Angela Tavares, Higa, Fabiana Shinzato [UNIFESP], Mendonca, Marcelo, Prata, Joao Antonio, Paranhos, Augusto [UNIFESP]
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNIFESP
Texto Completo: http://repositorio.unifesp.br/handle/11600/34914
http://dx.doi.org/10.1097/IJG.0b013e31820d7e4e
Resumo: Purpose: To compare the effect on intraocular pressure (IOP) of the silicone Ahmed glaucoma valve with and without an intravitreal injection of triamcinolone acetonide.Patients and Methods: Forty-nine patients with clinically uncontrolled neovascular glaucoma were included in the study; 22 were randomly assigned to the study group (silicone Ahmed glaucoma valve implant with intravitreal triamcinolone acetonide) and 27 to the control group (silicone Ahmed glaucoma valve). IOP was the primary outcome measure in this study. the secondary outcome measure was success, defined by IOP lower than 22 mm Hg and higher than 5 mm Hg, and no serious complications. Success rates in both the groups were compared using Kaplan-Meier survival curves and the log-rank test. IOP levels were compared using mixed linear model analysis to correct for repeated measures correlation.Results: Forty-three patients, 18 in the study group and 25 in the control group, completed the study (follow-up of 12 mo). the mean IOP was significantly lower after 1 year in both the groups (P < 0.001). the mean IOP in the first month of follow-up was lower in the study group (control; 20.4 +/- 9.7, study; 13.6 +/- 6.5, P < 0.01). the success rate at 1 year was 78% for the study group and 76% for the control group (P = 0.82). Complication rates were not different between the groups.Conclusions: Intravitreal injection of triamcinolone acetonide in neovascular glaucoma did not affect the intermediate-term success of the silicone Ahmed valve nor reduce the incidence of complications. the mean IOP spike in the first month was lower in the triamcinolone group.
id UFSP_5af5754ca65bc7bf7e2d7525cb559f04
oai_identifier_str oai:repositorio.unifesp.br:11600/34914
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling Teixeira, Sergio Henrique [UNIFESP]Doi, Larissa Morimoto [UNIFESP]Silva, Andre Luiz de Freitas [UNIFESP]Silva, Karine Duarte [UNIFESP]Paes, Angela TavaresHiga, Fabiana Shinzato [UNIFESP]Mendonca, MarceloPrata, Joao AntonioParanhos, Augusto [UNIFESP]Universidade Federal de São Paulo (UNIFESP)Hosp Israelita Albert EinsteinHORPUniv Fed Triangulo Mineiro2016-01-24T14:27:16Z2016-01-24T14:27:16Z2012-06-01Journal of Glaucoma. Philadelphia: Lippincott Williams & Wilkins, v. 21, n. 5, p. 342-348, 2012.1057-0829http://repositorio.unifesp.br/handle/11600/34914http://dx.doi.org/10.1097/IJG.0b013e31820d7e4e10.1097/IJG.0b013e31820d7e4eWOS:000305084100010Purpose: To compare the effect on intraocular pressure (IOP) of the silicone Ahmed glaucoma valve with and without an intravitreal injection of triamcinolone acetonide.Patients and Methods: Forty-nine patients with clinically uncontrolled neovascular glaucoma were included in the study; 22 were randomly assigned to the study group (silicone Ahmed glaucoma valve implant with intravitreal triamcinolone acetonide) and 27 to the control group (silicone Ahmed glaucoma valve). IOP was the primary outcome measure in this study. the secondary outcome measure was success, defined by IOP lower than 22 mm Hg and higher than 5 mm Hg, and no serious complications. Success rates in both the groups were compared using Kaplan-Meier survival curves and the log-rank test. IOP levels were compared using mixed linear model analysis to correct for repeated measures correlation.Results: Forty-three patients, 18 in the study group and 25 in the control group, completed the study (follow-up of 12 mo). the mean IOP was significantly lower after 1 year in both the groups (P < 0.001). the mean IOP in the first month of follow-up was lower in the study group (control; 20.4 +/- 9.7, study; 13.6 +/- 6.5, P < 0.01). the success rate at 1 year was 78% for the study group and 76% for the control group (P = 0.82). Complication rates were not different between the groups.Conclusions: Intravitreal injection of triamcinolone acetonide in neovascular glaucoma did not affect the intermediate-term success of the silicone Ahmed valve nor reduce the incidence of complications. the mean IOP spike in the first month was lower in the triamcinolone group.Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Universidade Federal de São Paulo, Dept Ophthalmol, São Paulo, BrazilHosp Israelita Albert Einstein, São Paulo, BrazilHORP, Sao Jose Do Rio Preto, SP, BrazilUniv Fed Triangulo Mineiro, Uberaba, MG, BrazilUniversidade Federal de São Paulo, Dept Ophthalmol, São Paulo, BrazilWeb of Science342-348engLippincott Williams & WilkinsJournal of Glaucomaneovascular glaucomaglaucoma drainage implantstriamcinolone acetonideSilicone Ahmed Glaucoma Valve With and Without Intravitreal Triamcinolone Acetonide for Neovascular Glaucoma: Randomized Clinical Trialinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP11600/349142022-09-27 14:37:28.671metadata only accessoai:repositorio.unifesp.br:11600/34914Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestopendoar:34652023-05-25T12:26:54.445903Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.en.fl_str_mv Silicone Ahmed Glaucoma Valve With and Without Intravitreal Triamcinolone Acetonide for Neovascular Glaucoma: Randomized Clinical Trial
title Silicone Ahmed Glaucoma Valve With and Without Intravitreal Triamcinolone Acetonide for Neovascular Glaucoma: Randomized Clinical Trial
spellingShingle Silicone Ahmed Glaucoma Valve With and Without Intravitreal Triamcinolone Acetonide for Neovascular Glaucoma: Randomized Clinical Trial
Teixeira, Sergio Henrique [UNIFESP]
neovascular glaucoma
glaucoma drainage implants
triamcinolone acetonide
title_short Silicone Ahmed Glaucoma Valve With and Without Intravitreal Triamcinolone Acetonide for Neovascular Glaucoma: Randomized Clinical Trial
title_full Silicone Ahmed Glaucoma Valve With and Without Intravitreal Triamcinolone Acetonide for Neovascular Glaucoma: Randomized Clinical Trial
title_fullStr Silicone Ahmed Glaucoma Valve With and Without Intravitreal Triamcinolone Acetonide for Neovascular Glaucoma: Randomized Clinical Trial
title_full_unstemmed Silicone Ahmed Glaucoma Valve With and Without Intravitreal Triamcinolone Acetonide for Neovascular Glaucoma: Randomized Clinical Trial
title_sort Silicone Ahmed Glaucoma Valve With and Without Intravitreal Triamcinolone Acetonide for Neovascular Glaucoma: Randomized Clinical Trial
author Teixeira, Sergio Henrique [UNIFESP]
author_facet Teixeira, Sergio Henrique [UNIFESP]
Doi, Larissa Morimoto [UNIFESP]
Silva, Andre Luiz de Freitas [UNIFESP]
Silva, Karine Duarte [UNIFESP]
Paes, Angela Tavares
Higa, Fabiana Shinzato [UNIFESP]
Mendonca, Marcelo
Prata, Joao Antonio
Paranhos, Augusto [UNIFESP]
author_role author
author2 Doi, Larissa Morimoto [UNIFESP]
Silva, Andre Luiz de Freitas [UNIFESP]
Silva, Karine Duarte [UNIFESP]
Paes, Angela Tavares
Higa, Fabiana Shinzato [UNIFESP]
Mendonca, Marcelo
Prata, Joao Antonio
Paranhos, Augusto [UNIFESP]
author2_role author
author
author
author
author
author
author
author
dc.contributor.institution.none.fl_str_mv Universidade Federal de São Paulo (UNIFESP)
Hosp Israelita Albert Einstein
HORP
Univ Fed Triangulo Mineiro
dc.contributor.author.fl_str_mv Teixeira, Sergio Henrique [UNIFESP]
Doi, Larissa Morimoto [UNIFESP]
Silva, Andre Luiz de Freitas [UNIFESP]
Silva, Karine Duarte [UNIFESP]
Paes, Angela Tavares
Higa, Fabiana Shinzato [UNIFESP]
Mendonca, Marcelo
Prata, Joao Antonio
Paranhos, Augusto [UNIFESP]
dc.subject.eng.fl_str_mv neovascular glaucoma
glaucoma drainage implants
triamcinolone acetonide
topic neovascular glaucoma
glaucoma drainage implants
triamcinolone acetonide
description Purpose: To compare the effect on intraocular pressure (IOP) of the silicone Ahmed glaucoma valve with and without an intravitreal injection of triamcinolone acetonide.Patients and Methods: Forty-nine patients with clinically uncontrolled neovascular glaucoma were included in the study; 22 were randomly assigned to the study group (silicone Ahmed glaucoma valve implant with intravitreal triamcinolone acetonide) and 27 to the control group (silicone Ahmed glaucoma valve). IOP was the primary outcome measure in this study. the secondary outcome measure was success, defined by IOP lower than 22 mm Hg and higher than 5 mm Hg, and no serious complications. Success rates in both the groups were compared using Kaplan-Meier survival curves and the log-rank test. IOP levels were compared using mixed linear model analysis to correct for repeated measures correlation.Results: Forty-three patients, 18 in the study group and 25 in the control group, completed the study (follow-up of 12 mo). the mean IOP was significantly lower after 1 year in both the groups (P < 0.001). the mean IOP in the first month of follow-up was lower in the study group (control; 20.4 +/- 9.7, study; 13.6 +/- 6.5, P < 0.01). the success rate at 1 year was 78% for the study group and 76% for the control group (P = 0.82). Complication rates were not different between the groups.Conclusions: Intravitreal injection of triamcinolone acetonide in neovascular glaucoma did not affect the intermediate-term success of the silicone Ahmed valve nor reduce the incidence of complications. the mean IOP spike in the first month was lower in the triamcinolone group.
publishDate 2012
dc.date.issued.fl_str_mv 2012-06-01
dc.date.accessioned.fl_str_mv 2016-01-24T14:27:16Z
dc.date.available.fl_str_mv 2016-01-24T14:27:16Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv Journal of Glaucoma. Philadelphia: Lippincott Williams & Wilkins, v. 21, n. 5, p. 342-348, 2012.
dc.identifier.uri.fl_str_mv http://repositorio.unifesp.br/handle/11600/34914
http://dx.doi.org/10.1097/IJG.0b013e31820d7e4e
dc.identifier.issn.none.fl_str_mv 1057-0829
dc.identifier.doi.none.fl_str_mv 10.1097/IJG.0b013e31820d7e4e
dc.identifier.wos.none.fl_str_mv WOS:000305084100010
identifier_str_mv Journal of Glaucoma. Philadelphia: Lippincott Williams & Wilkins, v. 21, n. 5, p. 342-348, 2012.
1057-0829
10.1097/IJG.0b013e31820d7e4e
WOS:000305084100010
url http://repositorio.unifesp.br/handle/11600/34914
http://dx.doi.org/10.1097/IJG.0b013e31820d7e4e
dc.language.iso.fl_str_mv eng
language eng
dc.relation.ispartof.none.fl_str_mv Journal of Glaucoma
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 342-348
dc.publisher.none.fl_str_mv Lippincott Williams & Wilkins
publisher.none.fl_str_mv Lippincott Williams & Wilkins
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv
_version_ 1783460292106125312